Nature Communications (Aug 2020)
PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance
- Elodie Montaudon,
- Joanna Nikitorowicz-Buniak,
- Laura Sourd,
- Ludivine Morisset,
- Rania El Botty,
- Léa Huguet,
- Ahmed Dahmani,
- Pierre Painsec,
- Fariba Nemati,
- Sophie Vacher,
- Walid Chemlali,
- Julien Masliah-Planchon,
- Sophie Château-Joubert,
- Camilla Rega,
- Mariana Ferreira Leal,
- Nikiana Simigdala,
- Sunil Pancholi,
- Ricardo Ribas,
- André Nicolas,
- Didier Meseure,
- Anne Vincent-Salomon,
- Cécile Reyes,
- Audrey Rapinat,
- David Gentien,
- Thibaut Larcher,
- Mylène Bohec,
- Sylvain Baulande,
- Virginie Bernard,
- Didier Decaudin,
- Florence Coussy,
- Muriel Le Romancer,
- Guillaume Dutertre,
- Zakia Tariq,
- Paul Cottu,
- Keltouma Driouch,
- Ivan Bièche,
- Lesley-Ann Martin,
- Elisabetta Marangoni
Affiliations
- Elodie Montaudon
- Translational Research Department, Institut Curie
- Joanna Nikitorowicz-Buniak
- Institute of Cancer Research
- Laura Sourd
- Translational Research Department, Institut Curie
- Ludivine Morisset
- Translational Research Department, Institut Curie
- Rania El Botty
- Translational Research Department, Institut Curie
- Léa Huguet
- Translational Research Department, Institut Curie
- Ahmed Dahmani
- Translational Research Department, Institut Curie
- Pierre Painsec
- Translational Research Department, Institut Curie
- Fariba Nemati
- Translational Research Department, Institut Curie
- Sophie Vacher
- Department of Genetics, Institut Curie
- Walid Chemlali
- Department of Genetics, Institut Curie
- Julien Masliah-Planchon
- Department of Genetics, Institut Curie
- Sophie Château-Joubert
- Alfort Veterinary School
- Camilla Rega
- Institute of Cancer Research
- Mariana Ferreira Leal
- Institute of Cancer Research
- Nikiana Simigdala
- Institute of Cancer Research
- Sunil Pancholi
- Institute of Cancer Research
- Ricardo Ribas
- Institute of Cancer Research
- André Nicolas
- Department of Pathology, Institut Curie
- Didier Meseure
- Department of Pathology, Institut Curie
- Anne Vincent-Salomon
- Department of Pathology, Institut Curie
- Cécile Reyes
- Translational Research Department, Institut Curie
- Audrey Rapinat
- Translational Research Department, Institut Curie
- David Gentien
- Translational Research Department, Institut Curie
- Thibaut Larcher
- INRA, APEX-PAnTher, Oniris
- Mylène Bohec
- Genomics of Excellence (ICGex) Platform, Institut Curie Research Center
- Sylvain Baulande
- Genomics of Excellence (ICGex) Platform, Institut Curie Research Center
- Virginie Bernard
- Department of Genetics, Institut Curie
- Didier Decaudin
- Translational Research Department, Institut Curie
- Florence Coussy
- Translational Research Department, Institut Curie
- Muriel Le Romancer
- Inserm U1052, Centre de Recherche en Cancérologie de Lyon
- Guillaume Dutertre
- Department of Surgery, Institut Curie
- Zakia Tariq
- Department of Genetics, Institut Curie
- Paul Cottu
- Department of Medical Oncology, Institut Curie
- Keltouma Driouch
- Department of Genetics, Institut Curie
- Ivan Bièche
- Department of Genetics, Institut Curie
- Lesley-Ann Martin
- Institute of Cancer Research
- Elisabetta Marangoni
- Translational Research Department, Institut Curie
- DOI
- https://doi.org/10.1038/s41467-020-17697-1
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 16
Abstract
Identifying novel therapies for the treatment of CDK4/6 inhibitor-resistant patients is of great importance. Here, the authors demonstrate that PLK1 inhibition is a potential therapeutic target in CCND1-driven and in RB-positive Palbociclib-resistant breast cancers.
